Review of the final report of the 1998 working party on definition, nomenclature and diagnosis of hepatic encephalopathy

Annals of Hepatology

Volumn 10, Issue SUPPL. 2, 2011, Pages

  Ramos, Juan Francisco Rivera ^a   Leal, Celina Rodríguez ^b  

^a HOSPITAL ESPAÑOL DE MÉXICO   (Mexico)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Guidelines; Hepatic encephalopathy; Neurophysiological testing; Neuropsychometric testing; Treatment

Indexed keywords

LACTULOSE; PLACEBO; RIFAXIMIN;

ACUTE LIVER FAILURE; DISEASE ASSOCIATION; HEALTH CARE MANAGEMENT; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER GRAFT; MEDICAL PRACTICE; MENTAL HEALTH; NEUROPHYSIOLOGY; NOMENCLATURE; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PRACTICE GUIDELINE; REVIEW;

EID: 79961180627     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31604-7     Document Type: Review

References (22)

1. Abou-Assi S, Vlahcevic ZR. Hepatic encephalopathy. Meta-bolic consequence of cirrhosis often is reversible. Post-grad Med 2001; 109(2): 52-4, 57-60, 63-5 passim.
2. Blei AT. Diagnosis and treatment of hepatic encephalopathy. Baillieres Best Pract Res Clin Gastroenterol 2000; 14(6): 959-74.
3. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature,diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35(3): 716-21.
4. Belanger M, Desjardins P, Chatauret N, Butterworth RF. Loss of expression of glial fibrillary acidic protein inacute hyperammonemia. Neurochem Int 2002; 41(2-3): 155-60.
5. Belanger M, Desjardins P, Chatauret N, Butterworth RF. Selectively increased expression of the astrocytic/endo-thelial glucose transporter protein GLUT1 in acute liver failure. Glia 2006; 53(5): 557-62.
6. Butterworth RF. Neuronal cell death in hepatic encephalopathy. Metab Brain Dis 2007; 22(3-4): 309-20.
7. Mullen KD. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepaticencephalopathy. Aliment Pharmacol Ther 2007; 25(Suppl.1): 11-6.
8. Gerber T, Schomerus H. Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management. Drugs2000; 60(6): 1353-70.
9. Prakash R, Mullen KD. Mechanisms, diagnosis and manage-ment of hepatic encephalopathy. Nat Rev GastroenterolHepatol 2010; 7(9): 515-25.
10. Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT. Impact of preoperative overt hepatic encephalopathy on neuro-cognitive function after liver transplantation. Liver Transpl 2009; 15(2): 184-92.
11. Mullen KD, Amodio P, Morgan MY. Therapeutic studies in hepatic encephalopathy. Metab Brain Dis 2007; 22(3-4):407-23.
12. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessmentof hepatic encephalopathy. Hepatology 2009; 50(6): 2014-21.
13. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hec-ker H. Neuropsychological characterization of hepatic en-cephalopathy. J Hepatol 2001; 34(5): 768-73.
14. Romero-Gomez M. Critical flicker frequency: it is time to break down barriers surrounding minimal hepatic encephalopathy. J Hepatol 2007; 47(1): 10-1.
15. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D. Critical flicker frequency for quantificationof low-grade hepatic encephalopathy. Hepatology 2002; 35(2): 357-66.
16. Mardini H, Saxby BK, Record CO. Computerized psychome-tric testing in minimal encephalopathy and modulation bynitrogen challenge and liver transplant. Gastroenterology 2008; 135(5): 1582-90.
17. Bajaj JS, Saeian K, Verber MD, et al. Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepa-tic encephalopathy. Am J Gastroenterol 2007; 102(4): 754-60.
18. Bass NM. Review article: the current pharmacological the-rapies for hepatic encephalopathy. Aliment PharmacolTher 2007; 25(Suppl. 1): 23-31.
19. Fanelli F, Salvatori FM, Rabuffi P, et al. Management of re-fractory hepatic encephalopathy after insertion of TIPS:long-term results of shunt reduction with hourglass-sha-ped balloon-expandable stent-graft. AJR Am J Roentgenol 2009; 193(6): 1696-702.
20. Alcorn J. Review: rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy. ACP J Club 2008; 149(5): 11.
21. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccha-rides for hepatic encephalopathy. Cochrane Database SystRev 2004; (2): CD003044.
22. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137(3): 885-91: 91e1.